Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Trudel, Suzanne
Bahlis, Nizar J.
Popat, Rakesh
Mateos, Maria-Victoria
Vangsted, Annette J.
Ramasamy, Karthik
Martinez-Lopez, Joaquin
Quach, Hang
Orlowski, Robert Z.
Burnett, Joseph
Gaudy, Allison
Chen, Wencong
Gong, Jing
Hadala, Joseph T.
Donahue, Cynthia
Koo, Phillip
Zhu, Yue
Katz, Jessica
Richardson, Paul G.
机构：
[1] Univ Toronto, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[3] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Fac, London, England
[4] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Centro Invest Canc IBMCC USAL, CSIC, Salamanca, Spain
[5] Rigshosp, Dept Hematol, Copenhagen, Denmark
[6] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England
[7] Univ Complutense Madrid, Hosp 12 Octubre, Dept Hematol,CIBERONC, H12O CNIO Clin Res Unit, Madrid, Spain
[8] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[10] Bristol Myers Squibb, Princeton, NJ USA
[11] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7539
引用
收藏
页数：1
相关论文
共 50 条
  • [1] OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis
    Robak, Tadeusz
    Delimpasi, Sosana
    Pour, Ludek
    Masszi, Tamas
    Spicka, Ivan
    Legiec, Wojciech
    Sonneveld, Pieter
    Thuresson, Marcus
    Larsson, Kajsa
    Harmenberg, Johan
    Schjesvold, Fredrik H.
    BLOOD, 2021, 138
  • [2] Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, P. G.
    Trudel, S.
    Popat, R.
    Mateos, M-, V
    Vangsted, A. J.
    Ramasamy, K.
    Martinez-Lopez, J.
    Quach, H.
    Orlowski, R. Z.
    Arnao, M.
    Lonial, S.
    Karanes, C.
    Pawlyn, C.
    Kim, K.
    Oriol, A.
    Berdeja, J. G.
    Rodriguez Otero, P.
    Casas-Aviles, I
    Spirli, A.
    Poon, J.
    Li, S.
    Gong, J.
    Wong, L.
    Lamba, M.
    Pierce, D. W.
    Amatangelo, M.
    Peluso, T.
    Maciag, P.
    Katz, J.
    Pourdehnad, Michael
    Bahlis, Nizar J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (11): : 1009 - 1022
  • [3] MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI)
    Matous, Jeffrey
    Siegel, David Samuel DiCapua
    Duong, Hien Kim
    Kasserra, Claudia
    Sternas, Lars
    Jacques, Christian
    Klesczewski, Kenneth
    Zaki, Mohamed H.
    Shah, Jatin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [5] MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low -Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis
    Sonneveld, Pieter
    Weisel, Katja C.
    Li, Yan
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Bacon, Pamela
    Dimopoulos, Meletios A.
    BLOOD, 2017, 130
  • [6] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [7] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul
    Sandhu, Irwindeep
    Oriol, Albert
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Perrot, Aurore
    Ocio, Enrique
    Raje, Noopur
    Hansen, Charlotte Toftmann
    Zhou, Zehua
    Civardi, Tiziana
    Ghiddi, Alessandro
    Katz, Jessica
    Peluso, Teresa
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
  • [8] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Sandhu, I
    Oriol, A.
    White, D.
    LeBlanc, R.
    Perrot, A.
    Ocio, E. M.
    Raje, N.
    Hansen, C. Toftmann
    Zhou, Z.
    Civardi, T.
    Katz, J.
    Peluso, T.
    Dimopoulos, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
  • [9] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios Athanasios
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna M.
    BLOOD, 2011, 118 (21) : 1263 - 1263
  • [10] OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis
    Dimopoulos, Meletios-Athanasios
    Schjesvold, Fredrik H.
    Mateos, Maria-Victoria
    Robak, Pawel J.
    Hajek, Roman
    Richardson, Paul G.
    Lindberg, Jakob
    Thuresson, Marcus
    Larsson, Kajsa
    Sonneveld, Pieter
    BLOOD, 2021, 138
12345